GlassScriptPhysician profile
Erica Hinds
NPI 1437880754
$2,111.08
in general payments reported to CMS, 2019-2025
15 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.56 · 2023: $677 · 2024: $1,218 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.63 | 2023-2025 | |
| Incyte Corporation | $263.42 | 2023-2024 | Opzelura |
| Galderma Laboratories, L.P. | $229.28 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $191.89 | 2023-2024 | Ilumya |
| Amgen INC. | $173.27 | 2023-2024 | Otezla |
| Janssen Biotech, INC. | $107.84 | 2023-2024 | Tremfya |
| Genzyme Corporation | $45.32 | 2024 | |
| Biofrontera INC. | $42.43 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $22.97 | 2023 | Seysara |
| Lilly USA, LLC | $22.27 | 2024 | Olumiant, Taltz |
| Leo Pharma INC. | $22.06 | 2024 | Adbry |
| Ucb, INC. | $21.79 | 2024 | Bimzelx |
| Verrica Pharmaceuticals INC. | $21.65 | 2023 | Ycanth |
| Solta Medical, A Division of Bausch Health US, LLC | $21.54 | 2022 | |
| Organon LLC | $5.72 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Hinds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.